Current Studies on abnobaVISCUM
Current completed studies
- Gastroenterology: Phase II study on advanced primary carcinoma of liver cells, 2004
(PDF Datei)
- Gynaecology: Phase II study on the epithelial ovarian carcinoma, 2005
(PDF Datei)
- Pharmacokinetic study: The high effective ingredients of abnobaVISCUM
enable the first pharmacokinetic study of a marketed mistletoe preparation (PDF Datei)
in cooperation with Chimera Biotec GmbH, Dortmund
www.chimera-biotec.com
(PDF Datei).
- Gynaecology/Quality of life: post marketing study on additive therapy with abnobaVISCUM
in breast cancer during chemo therapy; 2006 (PDF Datei).
Ongoing studies and application observations:
- Urology: Phase I/II study on the superficial bladder carcinoma (dose
finding); 2003 – 2005
- Gynaecology: post marketing study on additive therapy with abnobaVISCUM
in breast cancer; 2004 – 2007 (QLQ-C30 and QLQ BR23); Seoul, Korea
In preparation:
- Currently, studies on gastrological,
gynaecological and urological tumour therapies are being prepared
An evaluating overview of clinical studies on mistletoe therapy can be found in:
Kienle/ Kiene, Die Mistel in der Onkologie (Mistletoe in Oncology), Schattauer Verlag, 2003.
We recommend the following literature on current research in mistletoe therapy:
Scheer et al., Grundlagen der Misteltherapie (Fundamentals of Mistletoe Therapy), Hippokrates –Verlag, 1996
Scheer et al., Die Mistel in der Tumortherapie (Mistletoe in Tumour Therapy), KVC Verlag, 2001
Scheer et al., Fortschritte in der Misteltherapie (Progress in Mistletoe Therapy), KVC Verlag, 2005)